Image

Saudi Arabia Osteoporosis Drugs Market – Industry Trends and Forecast to 2029

Pharmaceutical

Image

Saudi Arabia Osteoporosis Drugs Market – Industry Trends and Forecast to 2029

  • Pharmaceutical
  • Published Report
  • Mar 2022
  • Country Level
  • 350 Pages
  • No of Tables: 20
  • No of Figures: 54

Saudi Arabia Osteoporosis Drugs Market, By Type (Primary Osteoporosis & Secondary Osteoporosis), Drugs (Bisphosphonates, Monoclonal Antibodies, Hormone Therapy & Others), Drugs Type (Branded & Generic), Route of Administration (Injectable, Oral & Others), Gender (Female & Male), Age Group (Geriatrics, Adults & Pediatrics), End User (Hospitals, Specialty Clinics, Homecare & Others), Distribution Channel (Direct Tender, Retail Sales & Others) Industry Trends and Forecasts to 2029.

Saudi Arabia Osteoporosis Drugs Market Analysis and Insights

According to the International Osteoporosis Foundation (IOF), ‘osteoporosis, which means porous bone, is a disease in which the quality and density of bone are reduced. As bones become more fragile and porous, the risk of fracture is greatly increased. The loss of bone occurs progressively and silently. Often there are no symptoms until the first fracture occurs.

With age, some of the bone cells begin to dissolve bone matrix, the process is called resorption, while new bone cells deposit osteoid, and the process is called formation. This process is called as remodeling. For people with osteoporosis, bone loss outpaces the growth of new bone. Bones become brittle, porous and prone to fracture. Though osteoporosis fractures can occur in other bones also, but he most commonly osteoporosis fractures occurs at wrist, spine or the hip.

The different types of medications for osteoporosis are available in the market. The bisphosphonates are usually the first choice for treatment of osteoporosis. These includes Risedronate (Actonel), a weekly or monthly pill, Alendronate (Fosamax), a weekly pill, Zoledronic acid (Reclast), an annual IV infusion and Ibandronate (Boniva), a monthly pill or quarterly intravenous (IV) infusion.

Data Bridge Market Research analyses that the Saudi Arabia osteoporosis drugs market will grow at a CAGR of 2.9% during the forecast period of 2022 to 2029.

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customizable to 2019 - 2014)

Quantitative Units

Revenue in USD Million, Pricing in USD

Segments Covered

Type (Primary Osteoporosis & Secondary Osteoporosis), Drugs (Bisphosphonates, Monoclonal Antibodies, Hormone Therapy & Others), Drugs Type (Branded & Generic), Route of Administration (Injectable, Oral & Others), Gender (Female & Male), Age Group (Geriatrics, Adults & Pediatrics), End User (Hospitals, Specialty Clinics, Homecare & Others), Distribution Channel (Direct Tender, Retail Sales & Others)

Countries Covered

Saudi Arabia

Market Players Covered

Eli Lilly and Company (U.S.), Novartis AG (Switzerland) , Amgen Inc. (U.S.), Tabuk pharmaceuticals (Saudi Arabia), SPIMACO (Saudi Arabia), Hikma Pharmaceuticals PLC (Jordan), Pfizer Inc. (U.S.) , Merck KGaA (Germany) , Apotex Inc. (Canada), ABIOGEN PHARMA S.p.A. (Italy), Sudair Pharma (Saudi Arabia), tadawipharma. (Saudi Arabia), Fresenius SE & Co. KGaA (Germany), Hayat Pharmaceutical Industries Co. PLC (Jordan), and SAJA Pharmaceuticals (Saudi Arabia)

Osteoporosis Drugs Market Dynamics

Drivers

  • Rise in Prevalence of Osteoporosis

Osteoporosis is a disease of bone which progresses due to the less bone mineral density and bone mass or due to some variation in the quality or structure of bone. Osteoporosis could increase the risk of fractures leading to broken bones due to decreased bone strength.

For instance,

  • According to the International Osteoporosis Foundation, the prevalence of low bone mass is higher in Middle East then in western countries. Though osteoporosis affects both males and females, females are likely to develop osteoporosis than men
  • Rise in geriatric population

As the geriatric population increases, osteoporosis and bone disorders are also rising among the older population. The aging population would refer to orthopedic centers which would increase the demand for osteoporosis treatment and hence is expected to as driver for the growth of Saudi Arabia osteoporosis drugs market.

Opportunities

  • Government Initiatives

The osteoporosis is often referred to as the “silent disease” as bone loss is painless and gradual, and there are usually no symptoms to indicate a person is developing osteoporosis. So government is taking initiative early secreening, diagnosis and treatment of disease in the country. Therefor, acting as opportunity for the growth of the market in coming years.

Restraints/Challenges

However, the side effects associated with osteoporosis drugs and high treatment cost will hamper the growth of the osteoporosis durgs market in Saudi Arabia. Additionally, slow progress in restructuring the healthcare system will further challenge the market in the forecast period mentioned above.

This osteoporosis durgs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on lab supplies market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Osteoporosis is a disease of bone which progresses due to the less bone mineral density and bone mass or due to some variation in the quality or structure of bone. According to the Ministry of Health of Saudi Arabia, in 2018, the prevalence of osteoporosis was 37% in the population above the age of 50 years.

According to the international journal of research in medical sciences, in 2014, 82% of Saudi women patients had vitamin D deficiency. Only 21% of women were exposed to sunlight, 58% of the women had low BMD, out of which 18% with osteoporosis and 40% with osteopenia.

Osteoporosis drugs market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohot multivariate statistical model for forecasting the market in growth period.

Post COVID-19 Impact on Lab Supplies Market

The COVID-19 has negatively affected the market. Lockdowns and isolations during pandemic complicates the disease management and medication adherence. The lack of access to healthcare facilities for routine treatment and medication administration will further impact the market.

Recent Development

  • In September 2021, Hikma Pharmaceuticals PLC announced that it has agreed to acquire Custopharm Inc. to grow the injectable and generic business segments of the company. Custopharm has received 13 US FDA approvals, with four first-to-market Abbreviated New Drug Application (ANDA) approvals - including one with Competitive Generic Therapy (CGT) designation - and one novel 505(b)(2) NDA approval.  This acquisition helped the company to increase its product portfolio and to further grow the overall revenue of the company.

Saudi Arabia Osteoporosis Drugs Market

Saudi Arabia Osteoporosis Drugs Market Scope

The osteoporosis drugs market is categorized into eight notable segments based on type, drugs, drugs type, route of administration, gender, age group, end user, and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

  • Primary Osteoporosis
  • Secondary Osteoporosis.

On the basis of type, Saudi Arabia osteoporosis drugs market is segmented into primary osteoporosis and secondary osteoporosis.

Drugs

  • Bisphosphonates
  • Monoclonal Antibodies
  • Hormone Therapy
  • Others

On the basis of drugs, Saudi Arabia osteoporosis drugs market is segmented into bisphosphonates, monoclonal antibodies, hormone therapy and others.

Drugs Type

  • Branded
  • Generic

On the basis of drugs type, Saudi Arabia osteoporosis drugs market is segmented into branded and generic.

Route of Administration

  • Injectable
  • Oral
  • Others

On the basis of route of administration, Saudi Arabia osteoporosis drugs market is segmented into injectable, oral and others.

Gender

  • Female
  • Male

On the basis of gender, Saudi Arabia osteoporosis drugs market is segmented into female and male.

Age Group

  • Geriatrics
  • Adults
  • Pediatrics

On the basis of age group, Saudi Arabia osteoporosis drugs market is segmented into geriatrics, adults and pediatrics.

End User

  • Hospitals
  • Specialty Clinics
  • Homecare
  • Others

On the basis of end user, Saudi Arabia osteoporosis drugs market is segmented into hospitals, specialty clinics, homecare and others.

Distribution Channel

  • Direct Tender
  • Retail Sales
  • Others

On the basis of distribution channel, Saudi Arabia osteoporosis drugs market is segmented into direct tender, retail sales and others.

Pipeline Analysis

The pipeline analysis of osteoporosis drugs market includes various pipeline therapies such as Ibandronate, Risedronate Sodium, Ibandroante (Bonviva/Boniva), Strontium Ranelate. F. Hoffman-La Roche Ltd, Sanofi, Nycomed, Elly Lilly and Company and Nordic Biosciences A/S among others are involved in the development of potential drugs for the improvement of treatment of osteoporosis.

Competitive Landscape and Osteoporosis Drugs Market Share Analysis

The osteoporosis durgs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, Saudi Arabia presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to osteoporosis durgs market.

Some of the major players operating in the Saudi Arabia osteoporosis drugs market are Eli Lilly and Company, Novartis AG, Amgen Inc., Tabuk pharmaceuticals, SPIMACO, Hikma Pharmaceuticals PLC, Pfizer Inc., Merck KGaA, Apotex Inc., ABIOGEN PHARMA S.p.A., Sudair Pharma, tadawipharma., Fresenius SE & Co. KGaA, Hayat Pharmaceutical Industries Co. PLC, and SAJA Pharmaceuticals among others.


SKU-

TABLE 1 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET, PIPELINE ANALYSIS

TABLE 2 PROJECTED NUMBER OF OSTEOPOROSIS PATIENTS, BY COUNTRY, 2021-2026, (IN UNITS)

TABLE 3 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET, DIAGNOSIS RATE, 2021-2026, (IN %)

TABLE 4 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET, TREATMENT RATE, 2021-2026, (IN %)

TABLE 5 COST ESTIMATION OF PATIENTS WITH OSTEOPOROSIS

TABLE 6 ESTIMATED COST OF MEDICATIONS FOR THE TREATMENT OF OSTEOPOROSIS

TABLE 7 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 8 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET, BY DRUGS, 2020-2029 (USD MILLION)

TABLE 9 SAUDI ARABIA BISPHOSPHONATES IN OSTEOPOROSIS DRUGS MARKET, BY DRUGS, 2020-2029 (USD MILLION)

TABLE 10 SAUDI ARABIA MONOCLONAL ANTIBODIES IN OSTEOPOROSIS DRUGS MARKET, BY DRUGS, 2020-2029 (USD MILLION)

TABLE 11 SAUDI ARABIA HORMONE THERAPY IN OSTEOPOROSIS DRUGS MARKET, BY DRUGS, 2020-2029 (USD MILLION)

TABLE 12 SAUDI ARABIA ESTROGEN IN OSTEOPOROSIS DRUGS MARKET, BY DRUGS, 2020-2029 (USD MILLION)

TABLE 13 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET, BY DRUGS TYPE, 2020-2029 (USD MILLION)

TABLE 14 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 15 SAUDI ARABIA ORAL IN OSTEOPOROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 16 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET, BY GENDER, 2020-2029 (USD MILLION)

TABLE 17 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)

TABLE 18 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 19 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 20 SAUDI ARABIA RETAIL SALES IN OSTEOPOROSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

Please fill in the below form for Infographics

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Research Methodology:

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Please fill in the below form for Research Methodology

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Customization Available:

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Please fill in the below form for Available Customization

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

FREQUENTLY ASK QUESTIONS

The Saudi Arabia Osteoporosis Drugs Market will be projected to grow at a CAGR of 2.9% during the forecast by 2029.
The side effects associated with osteoporosis drugs and high treatment cost are poised to restrict the growth of Saudi Arabia Osteoporosis Drugs Market.
Eli Lilly and Company (U.S.), Novartis AG (Switzerland) , Amgen Inc. (U.S.), Tabuk pharmaceuticals (Saudi Arabia), SPIMACO (Saudi Arabia), Hikma Pharmaceuticals PLC (Jordan), Pfizer Inc. (U.S.) , Merck KGaA (Germany) , Apotex Inc. (Canada), ABIOGEN PHARMA S.p.A. (Italy), Sudair Pharma (Saudi Arabia), tadawipharma. (Saudi Arabia), Fresenius SE & Co. KGaA (Germany), Hayat Pharmaceutical Industries Co. PLC (Jordan), and SAJA Pharmaceuticals (Saudi Arabia) are the major players operating in the Saudi Arabia Osteoporosis Drugs Market.
Rise in Prevalence of Osteoporosis, and Rise in geriatric population are the significant factors flourishing the growth of the Saudi Arabia Osteoporosis Drugs Market.
Free Sample Report

CHOOSE LICENCE TYPE

  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 7500.00

Why Choose Us

Industry Coverage

DBMR works across the globe in multiple industries which equip us with knowledge across verticals and provide our clients with insights not only from their industry but how other industries will impact their ecosystem.

Regional Coverage

Coverage of Data Bridge is not restricted to developed or emerging economies. We work across the globe covering the largest array of countries where no other market research or business consulting firm has ever conducted research; creating growth opportunities for our clients in areas which are still unknown.

Technology Coverage

In today’s world, technology drives the market sentiment, so our vision is to provide our clients insights not only for developed technologies but upcoming and disrupting technological changes throughout the product lifecycle by enabling them with unforeseen opportunities in the market which will create disruption in their industry. This leads to innovation and our clients to come out as winners.

Goal Oriented Solutions

DBMR goal is to help our clients achieve their goals through our solutions; hence we formatively create the most appropriate solutions for our client needs, saving time and efforts for them to drive their grand strategies.

Unparallel Analyst Support

Our analysts take pride in our clients’ success. Unlike others, we believe in working along our clients to achieve their goals with 24 hours analyst support determining the correct needs and inspire innovation through service.

Banner

Client Testimonials